Synthesis of new 4-butyl-arylpiperazine-3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives and evaluation for their 5-HT1A and D2 receptor affinity and serotonin transporter inhibition

被引：15

作者：

Wrobel, Martyna Z. ^{[1
]}

Chodkowski, Andrzej ^{[1
]}

Marciniak, Monika ^{[1
]}

Dawidowski, Maciej ^{[1
]}

Maksymiuk, Anna ^{[1
]}

Siwek, Agata ^{[2
]}

Nowak, Gabriel ^{[2
,3
]}

Turlo, Jadwiga ^{[1
]}

机构：

[1] Med Univ Warsaw, Fac Pharm, Dept Drug Technol & Pharmaceut Biotechnol, 1 Banacha St, PL-02097 Warsaw, Poland

[2] Jagiellonian Univ, Fac Pharm, Dept Pharmacobiol, Med Coll, 9 Med St, PL-30688 Krakow, Poland

[3] Polish Acad Sci, Maj Inst Pharmacol, Dept Neurobiol, 12 Smetna St, PL-31343 Krakow, Poland

来源：

BIOORGANIC CHEMISTRY | 2020年 / 97卷

关键词：

Long-chain arylpiperazines; Depression; 5-HT1A receptor ligands; Schizophrenia; Multi-target ligands; DOPAMINE D-3; CNS AGENTS; ANTIDEPRESSANT; LIGANDS; ANALOGS; BINDING; PATHOPHYSIOLOGY; DEPRESSION; VILAZODONE; DISCOVERY;

D O I：

10.1016/j.bioorg.2020.103662

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A series of novel 4-butyl-arylpiperazine-3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives were synthesized and evaluated for their 5-HT1A/D-2 receptor affinity and serotonin reuptake inhibition. The compounds exhibited high affinity for the 5-HT1A receptor, (especially 4d K-i = 0.4 nM) which depended on the substitution pattern at the phenylpiperazine moiety. From this series screen, compound 4c emerged with promising mixed receptor profiles for the 5-HT1A/D-2 receptors and the serotonin transporter (K-i = 1.3 nM, 182 nM and 64 nM, respectively).

引用

收藏

页数：9

相关论文

共 48 条

[31] STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF CNS AGENTS .23. N-(3-PHENYLPROPYL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE AND N-[(E)-CINNAMYL]-1,2,3,4-TETRAHYDRO-ISOQUINOLINE MIMIC 1-PHENYLPIPERAZINE AT 5-HT1A RECEPTORS [J].

MOKROSZ, JL ;

BOJARSKI, AJ ;

CHARAKCHIEVAMINOL, S ;

DUSZYNSKA, B ;

MOKROSZ, MJ ;

PALUCHOWSKA, MH .

ARCHIV DER PHARMAZIE, 1995, 328 (7-8) :604-608

[32] Struture-activity relationship studies of CNS agents .26. 4-[2-(Cycloalkanecarboxamido)ethyl]-1-(2-methoxyphenyl)-piperazines: High-affinity 5-HT1A agonists [J].

Mokrosz, JL ;

Paluchowska, MH ;

Klodzinska, A ;

CharakchievaMinol, S ;

ChojnackaWojcik, E .

ARCHIV DER PHARMAZIE, 1995, 328 (11-12) :770-774

[33] Serotonin receptor and transporter ligands - Current status [J].

Oh, SJ ;

Ha, HJ ;

Chi, DY ;

Lee, HK .

CURRENT MEDICINAL CHEMISTRY, 2001, 8 (09) :999-1034

[34] On the bioactive conformation of NAN-190 (1) and MP3022 (2), 5-HT1A receptor antagonists [J].

Paluchowska, MH ;

Mokrosz, MJ ;

Bojarski, A ;

Wesolowska, A ;

Borycz, J ;

Charakchieva-Minol, S ;

Chojnacka-Wójcik, E .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (24) :4952-4960

[35]

Paluchowska MH, 2003, POL J PHARMACOL, V55, P543

[36] The impact of the halogen bonding on D2 and 5-HT1A/5-HT7 receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl] phenylpiperazines with antipsychotic and antidepressant properties [J].

Partyka, Anna ;

Kurczab, Rafal ;

Canale, Vittorio ;

Satala, Grzegorz ;

Marciniec, Krzysztof ;

Pasierb, Agnieszka ;

Jastrzebska-Wiesek, Magdalena ;

Pawlowski, Maciej ;

Wesolowska, Anna ;

Bojarski, Andrzej J. ;

Zajdel, Pawel .

BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (14) :3638-3648

[37] Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT1A receptor functional profile [J].

Partyka, Anna ;

Chlon-Rzepa, Grazyna ;

Wasik, Anna ;

Jastrzebska-Wiesek, Magdalena ;

Bucki, Adam ;

Kolaczkowski, Marcin ;

Satala, Grzegorz ;

Bojarski, Andrzej J. ;

Wesolowska, Anna .

BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (01) :212-221

[38] Synthesis, 5-HT1A and 5-HT2A receptor affinity of new 1-phenylpiperazinylpropyl derivatives of purine-2,6-and pyrrolidine-2,5-diones [J].

Pawlowski, M ;

Chlon, G ;

Obniska, J ;

Zejc, A ;

Charakchieva-Minol, S ;

Mokrosz, MJ .

FARMACO, 2000, 55 (6-7) :461-468

[39] The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review [J].

Sinyor, Mark ;

Schaffer, Ayal ;

Levitt, Anthony .

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2010, 55 (03) :126-135

[40] Modeling of the D2 dopamine receptor arylpiperazine binding site for 1-{2-[5-(1H-benzimidazoIe-2-thione)]ethyl}-4-arylpiperazines [J].

Sukalovic, V ;

Zlatovic, M ;

Andric, D ;

Roglic, G ;

Kostic-Rajacic, S ;

Soskic, V .

ARCHIV DER PHARMAZIE, 2004, 337 (09) :502-512

← 1 2 3 4 5 →